Takeda Pharmaceutical Company Limited





Market Closed - Japan Exchange 02:00:00 2024-06-18 EDT 5-day change 1st Jan Change
4,044 JPY -2.95% Intraday chart for Takeda Pharmaceutical Company Limited -4.15% -0.25%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Takeda's Soticlestat Shows Promising Secondary Outcomes in Phase 3 Studies for Dravet and Lennox-Gastaut Syndromes MT
Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback DJ
Sector Update: Health Care Stocks Decline Premarket Monday MT
Investors Look for Fresh Impetus Ahead of Holiday Break, Stifling US Equity Futures Pre-Bell MT
Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall MT
Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints MT
Takeda's Soticlestat Misses Goals in Phase 3 Epilepsy Studies DJ
Takeda's seizure drug fails to meet main goal in late-stage studies RE
Takeda Pharmaceutical Company Limited Announces Topline Data from its Phase 3 SKYLINE and SKYWAY Studies Evaluating Soticlestat for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome CI
Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome CI
Takeda Signs Option Agreement with Ascentage to License Leukemia Drug MT
Takeda Pharmaceutical Company Limited Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, Third-Generation BCR-ABL Tyrosine Kinase Inhibitor CI
Takeda Issues New Shares, Disposes of Treasury Shares Under Long-term Incentive Plan for Employees MT
Takeda Pharmaceutical Prices Second Hybrid Bonds for 460 Billion Yen MT
Former Takeda Employee Pleads Guilty to Defrauding Company DJ
Takeda Pharmaceutical Unit Partners with HEALWELL AI for Real-World Evidence Analysis of Hereditary Angioedema MT
Torrent Pharma Signs Deal with Japan's Takeda to Market Acid-Related Disorders Drug in India MT
Transcript : Takeda Pharmaceutical Company Limited - Special Call
Takeda Pharmaceutical, Pfizer Say Phase 3 Trial Assessing Blood Cancer Combination Therapy Met Co-Primary Endpoints MT
Takeda Says Narcolepsy Drug Meets Main, Secondary Goals in Trial MT
Takeda Pharmaceutical Company Limited to Present Positive Results from its Phase 2B Trial of TAK-861 CI
GSK blood cancer drug nearly halves risk of death in late-stage trial RE
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma CI
Takeda Pharmaceutical Says Recombinant ADAMTS13 Gets Approval Recommendation From European Medicines Agency's CHPM MT
Takeda Gets CHMP Approval for Recombinant ADAMTS13 DJ
Chart Takeda Pharmaceutical Company Limited
More charts
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas: - sale of drugs and consumer care products; - services. Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
4,167 JPY
Average target price
4,768 JPY
Spread / Average Target
  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. News Takeda Pharmaceutical Company Limited
  5. EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug